Norwegian innovators are pioneering cancer treatment
Page date: published 8 March 2023; updated 3 June 2026; 4 min read (as rendered).
The article presents Norway’s precision-oncology ecosystem through Nykode Therapeutics, Oslo Cancer Cluster, IMPRESS-Norway and publicly funded hospital research. Nykode (formerly Vaccibody) develops cancer vaccines and immunotherapies. The page reports 2023 Phase 2 results for candidate VB10.16 in advanced cervical cancer and says survival rates were nearly double compared with then-current alternatives; this is a source-reported trial result, not a treatment recommendation.
It names Nykode’s international collaborations with Regeneron, Genentech, Nektar Therapeutics and Adaptive Biotechnologies and lists other Norwegian oncology companies including BerGenBio, EXACT Therapeutics, Lytix Biopharma, Thor Medical, PCI Biotech, Photocure, Targovax and Ultimovacs. The article describes Oslo Cancer Cluster as a roughly 90-member nonprofit supporting cancer research and public-private partnerships.
IMPRESS-Norway is described as a nationwide trial testing medicines for advanced cancer after standard treatment, with 20 pharmaceutical-company collaborators cited, including Eli Lilly, Incyte, Novartis and Roche. The page also mentions NorTrials, the Nordic Precision Medical Trial Network, the CONNECT consortium, InPreD diagnostics infrastructure, and INSIGHT research into regulatory implementation. It emphasizes shared hospital participation, public funding for diagnostics and early drug cohorts, Biobank Norway and national health registries as enabling infrastructure.
Claims about trial results, company status, network membership and ongoing programs reflect the article and may have changed. This is informational, not medical advice.
Related link: Health and life science.